Memantine Hydrochloride Aspire Pharma (Memantine Hydrochloride)

The drug acts as a non‑competitive antagonist at NMDA receptors, blocking excessive calcium entry caused by glutamate over‑activation. This reduces excitotoxic neuronal damage, which is a key factor in the progression of Alzheimer’s disease.

The dosing regimen for Memantine Hydrochloride is determined by the prescribing clinician based on the patient’s condition, age, renal function and other factors. The prescriber will set the appropriate dose and titration schedule.

Safety data for Memantine Hydrochloride in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas many other Alzheimer’s treatments are acetylcholinesterase inhibitors. Memantine targets glutamate‑mediated excitotoxicity, offering a different mechanism that can be used alone or in combination with acetylcholinesterase inhibitors for broader symptom control.

Store the product at ambient temperature, preferably below 25 °C. Keep it in the original packaging to protect from moisture and light. Do not store in extreme heat or humidity, and keep out of reach of children.

Memantine Hydrochloride is taken orally, usually as a tablet. The medication should be swallowed whole with water and can be taken with or without food, following the prescriber’s instructions regarding timing and dose adjustments.

Serious risks include the potential for seizures, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic injury. Patients should be monitored for any signs of these events, and treatment should be discontinued immediately if they occur.

Memantine Hydrochloride should be avoided in patients with known hypersensitivity to the drug, those taking other NMDA antagonists, and individuals with uncontrolled severe renal impairment unless dose adjustments are made. Clinicians should also assess risk in patients with a history of seizures.